Galectin Therapeutics reports a Q1 GAAP loss of $0.08 per share, exceeding analyst expectations by $0.02.
Galectin Therapeutics posted a Q1 GAAP loss of $0.08 per share, missing estimates by $0.02. The wider-than-expected loss reflects ongoing operational costs and investment in clinical development.
As of March 31, 2026, the company held $14.1 million in cash and cash equivalents, along with $10 million remaining under a line of credit provided by its chairman. The financial position remains stable but underscores the need for additional funding or cost management.
No immediate market reaction was disclosed in the release.